Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Sarcoma × chiauranib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 4 Recurrence 4 Ovarian Neoplasms 3 Lymphoma, Non-Hodgkin 2 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Sarcoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 30 pembrolizumab 12 Gemcitabine 11 Irinotecan 9 pazopanib 8 eribulin 8 Trabectedin 8 olaratumab 7 Cyclophosphamide 6 anlotinib 5 Injections 5 Docetaxel 5 ridaforolimus 4 Temozolomide 4 Nivolumab 4 Ifosfamide 4 Fluorouracil 4 Carboplatin 4 Bevacizumab 4 tazemetostat 3 belinostat 3 TH 302 3 Paclitaxel 3 Ipilimumab 3 Epirubicin 3 Drug Therapy 3 Dacarbazine 3 DOXO-EMCH 3 trastuzumab deruxtecan 2 toripalimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05497843 2025-04-03

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Chipscreen Biosciences, Ltd.

Phase 2 Completed

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡